TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: A Prospective Study

To evaluate the response to aflibercept therapy for Type 1 and Type 3 neovascularization in pigment epithelial detachments associated with treatment-naive, neovascular age-related macular degeneration. In this multicentered, prospective study, eligible eyes underwent an intravitreal aflibercept inje...

Full description

Saved in:
Bibliographic Details
Published in:Retina (Philadelphia, Pa.) Vol. 36 Suppl 1; p. S50
Main Authors: Chen, Xuejing, Al-Sheikh, Mayss, Chan, Clement K, Hariri, Amir H, Abraham, Prema, Lalezary, Maziar, Lin, Steven G, Sadda, SriniVas, Sarraf, David
Format: Journal Article
Language:English
Published: United States 01.12.2016
Subjects:
Aged
Aged, 80 and over
Angiogenesis Inhibitors - administration & dosage
Female
Geographic Atrophy - complications
Geographic Atrophy - diagnosis
Geographic Atrophy - physiopathology
Humans
Intravitreal Injections
Macular Degeneration - complications
Macular Degeneration - diagnostic imaging
Macular Degeneration - physiopathology
Male
Prospective Studies
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Recombinant Fusion Proteins - administration & dosage
Retinal Detachment - diagnostic imaging
Retinal Detachment - etiology
Retinal Detachment - physiopathology
Retinal Neovascularization - complications
Retinal Neovascularization - drug therapy
Retinal Neovascularization - physiopathology
Tomography, Optical Coherence - methods
Treatment Outcome
Visual Acuity - physiology
ISSN:1539-2864
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the response to aflibercept therapy for Type 1 and Type 3 neovascularization in pigment epithelial detachments associated with treatment-naive, neovascular age-related macular degeneration. In this multicentered, prospective study, eligible eyes underwent an intravitreal aflibercept injection protocol for 12 months. Visual acuity and morphologic features of the pigment epithelial detachments were compared at baseline and follow-up intervals between eyes with Type 1 versus Type 3 neovascularization. Thirty-six eyes were analyzed. At 12 months, Type 1 lesions showed a 4.5 ± 23 Early Treatment of Diabetic Retinopathy Study letter improvement (P = 0.1665) versus a 14 ± 11 (P = 0.0072) letter improvement with Type 3 lesions. Both Type 1 and 3 eyes showed a significant decrease in pigment epithelial detachment size, subretinal fluid, and subretinal hyperreflective material; however, Type 3 eyes had a greater reduction in pigment epithelial detachment size and subretinal hyperreflective material, as well as a reduction in central retinal thickness. Type 1 eyes required an average of 1.636 (range, 1-4) injections to resolve fluid, which was greater than Type 3 eyes, which required an average of 1.143 (range, 1-2) injections (P = 0.0251). Intravitreal aflibercept injections were efficacious for pigment epithelial detachments, but baseline and follow-up anatomical and functional outcomes differed in Type 1 versus Type 3 neovascularization. The better response of Type 3 eyes with fewer injections suggests that differentiation of the neovascularization subtype at the initial diagnosis may allow for a more tailored, optimal therapy.
ISSN:1539-2864
DOI:10.1097/IAE.0000000000001271